What's new?

Sofinnova Partners closes €445M ($540M) oversubscribed late-stage healthcare crossover fund

The pioneering growth capital fund is the largest dedicated to biopharma and medtech companies seeking scale-up financing in Europe With over €2 billion under management, Sofinnova Partners continues its expansion across the entire value chain of life sciences investments, from seed to later-stage PARIS, France – M...

Michelin and Pyrowave Join Forces to Industrialize an Innovative Plastic Waste Recycling Technology

- Michelin Group and the Canadian firm Pyrowave join forces to accelerate time-to-market for an innovative plastic waste recycling technology. - They agree to fast track the process industrialization. - The purpose of the technology is to increase the rate of sustainable materials not only in Michelin tires, but al...

TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant

IDE Approval Clears Path to U.S. Clinical Trial Launch for Vascular Sealant   TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption...

Myricx Pharma Launches with £4.5M Financing to Progress its Novel NMT inhibitors in Cancer

● Start-up from Imperial College London and the Francis Crick Institute brings together 15 years of world-leading research on N-myristoyltransferase (NMT) and breakthrough discoveries related to its inhibition in cancer ● Initial financing of £4.5M from venture capital syndicate of experienced life sciences investo...

Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

Nov 8, 2020,   Calliditas Therapeutics AB (OMX Nasdaq: CALTX, NASDAQ: CALT) (”Calliditas”) today announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon® versus placebo in patients with primary IgA nephropathy (IgAN).

GenSight Biologics reports validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency

Paris, France, Tuesday, November 3, 2020, 7.30 am CET    GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported tha...

Inventiva announces the publication of a scientific paper on the role of PPARs in the treatment of NASH in the medical journal Nature Review Gastroenterology & Hepatology

Daix (France), November 2, 2020   Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medica...

Redx Pharma announces appointment of leading oncology drug developer, Dr Jane Robertson, as Chief Medical Officer

Alderley Park, 27 October 2020,   Redx Pharma plc (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, is pleased to announce that it has appointed Dr Jane Robertson as Chief Medical Officer.     Jane is a well respected UK haemato-oncologist with over 17 years' experience of clin...

Gensight Biologics Successfully Raises €25 Million in an Oversubscribed Private Placement With Us and European Institutional Investors

October 22, 2020 12:30 AM Eastern Daylight Time   PARIS--BUSINESS WIRE --Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the "Company"), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative di...

CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects

CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE)    CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that they have dosed the first subject in the brigHTN study. The brigHTN study is a Phase 2 clinical trial evaluating the ...

Dr. Joe Anderson Joins Sofinnova Partners

Dr. Anderson’s appointment as Partner in the Crossover Fund reflects the venture capital firm’s continuing expansion across the entire value chain of life sciences investments, from seed to later-stage   PARIS, France – October 14, 2020    Sofinnova Partners, a leading European life sciences venture capital firm ba...

1 2 3 4 5 ... 183